Literature DB >> 22609298

Altered synaptic transmission in the hippocampus of transgenic mice with enhanced central nervous systems expression of interleukin-6.

T E Nelson1, A Olde Engberink, R Hernandez, A Puro, S Huitron-Resendiz, C Hao, P N E De Graan, D L Gruol.   

Abstract

Elevated levels of the inflammatory cytokine interleukin-6 (IL-6) occur in a number of CNS disorders. However, little is known about how this condition affects CNS neuronal function. Transgenic mice that express elevated levels of IL-6 in the CNS show cognitive changes, increased propensity for hippocampal seizures and reduced number of inhibitory interneurons, suggesting that elevated levels of IL-6 can cause neuroadaptive changes that alter hippocampal function. To identify these neuroadaptive changes, we measured the levels of protein expression using Western blot analysis and synaptic function using field potential recordings in hippocampus from IL-6 transgenic mice (IL-6 tg) and their non-transgenic (non-tg) littermates. Western blot analysis showed enhanced levels of the GFAP and STAT3 in the IL-6 tg hippocampus compared with the non-tg hippocampus, but no difference for several other proteins. Field potential recordings of synaptic transmission at the Schaffer collateral to CA1 synapse showed enhanced dendritic excitatory postsynaptic potentials and somatic population spikes in the CA1 region of hippocampal slices from IL-6 tg mice compared with slices from non-tg littermate controls. No differences were observed for several forms of short-term and long-term synaptic plasticity between hippocampal slices from IL-6 tg and non-tg mice. These results demonstrate that elevated levels of IL-6 can alter mechanisms involved in the excitability of hippocampal neurons and synapses, an effect consistent with recent evidence indicating that elevated production of IL-6 plays an important role in conditions associated with seizure activity and in other impairments observed in CNS disorders with a neuroinflammatory component.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609298      PMCID: PMC3427030          DOI: 10.1016/j.bbi.2012.05.005

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  74 in total

Review 1.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

2.  Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus.

Authors:  R Creager; T Dunwiddie; G Lynch
Journal:  J Physiol       Date:  1980-02       Impact factor: 5.182

3.  Adenosine increases synaptic facilitation in the in vitro rat hippocampus: evidence for a presynaptic site of action.

Authors:  T V Dunwiddie; H L Haas
Journal:  J Physiol       Date:  1985-12       Impact factor: 5.182

4.  Acute exposure to CXC chemokine ligand 10, but not its chronic astroglial production, alters synaptic plasticity in mouse hippocampal slices.

Authors:  Roman Vlkolinský; George R Siggins; Iain L Campbell; Thomas Krucker
Journal:  J Neuroimmunol       Date:  2004-05       Impact factor: 3.478

5.  Profound increase in sensitivity to glutamatergic- but not cholinergic agonist-induced seizures in transgenic mice with astrocyte production of IL-6.

Authors:  Helen Samland; Salvador Huitron-Resendiz; Eliezer Masliah; Jose Criado; Steven J Henriksen; Iain L Campbell
Journal:  J Neurosci Res       Date:  2003-07-15       Impact factor: 4.164

6.  Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats.

Authors:  Allan V Kalueff; Kai A Lehtimaki; Aarne Ylinen; Jari Honkaniemi; Jukka Peltola
Journal:  Neurosci Lett       Date:  2004-07-22       Impact factor: 3.046

7.  Seizure susceptibility to various convulsant stimuli of knockout interleukin-6 mice.

Authors:  Giovambattista De Sarro; Emilio Russo; Guido Ferreri; Bruzzese Giuseppe; Maria Antonietta Flocco; Eugenio Donato Di Paola; Angela De Sarro
Journal:  Pharmacol Biochem Behav       Date:  2004-04       Impact factor: 3.533

8.  Regulation of IL-6 system in cerebrospinal fluid and serum compartments by seizures: the effect of seizure type and duration.

Authors:  K A Lehtimäki; T Keränen; H Huhtala; M Hurme; J Ollikainen; J Honkaniemi; J Palmio; J Peltola
Journal:  J Neuroimmunol       Date:  2004-07       Impact factor: 3.478

9.  Susceptibility to audiogenic seizure and neurotransmitter amino acid levels in different brain areas of IL-6-deficient mice.

Authors:  Grazia De Luca; Rosa Maria Di Giorgio; Salvatore Macaione; Pina Rita Calpona; Santa Costantino; Eugenio Donato Di Paola; Angela De Sarro; Gennaro Ciliberto; Giovambattista De Sarro
Journal:  Pharmacol Biochem Behav       Date:  2004-05       Impact factor: 3.533

10.  Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid.

Authors:  P Gallo; K Frei; C Rordorf; J Lazdins; B Tavolato; A Fontana
Journal:  J Neuroimmunol       Date:  1989-07       Impact factor: 3.478

View more
  27 in total

Review 1.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 2.  Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus.

Authors:  Meggan Mackay
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

3.  Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex.

Authors:  Francisco Garcia-Oscos; David Peña; Mohammad Housini; Derek Cheng; Diego Lopez; Michael S Borland; Roberto Salgado-Delgado; Humberto Salgado; Santosh D'Mello; Michael P Kilgard; Stefan Rose-John; Marco Atzori
Journal:  Brain Behav Immun       Date:  2014-08-13       Impact factor: 7.217

Review 4.  Adipokines: a link between obesity and dementia?

Authors:  Amanda J Kiliaan; Ilse A C Arnoldussen; Deborah R Gustafson
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

5.  Trans-resveratrol attenuates high fatty acid-induced P2X7 receptor expression and IL-6 release in PC12 cells: possible role of P38 MAPK pathway.

Authors:  Hong Xu; Chaopeng Xiong; Luling He; Bing Wu; Lulu Peng; Yajun Cheng; Fuqing Jiang; Liping Tan; Lan Tang; Yunming Tu; Yuping Yang; Changle Liu; Yun Gao; Guilin Li; Chunping Zhang; Shuangmei Liu; Changshui Xu; Hong Wu; Guodong Li; Shangdong Liang
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

6.  Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ERK, and PI3K/AKT signaling pathways.

Authors:  Xiao-Xia Fang; Xiao-Lin Jiang; Xin-Hua Han; Yu-Ping Peng; Yi-Hua Qiu
Journal:  Cell Mol Neurobiol       Date:  2012-11-16       Impact factor: 5.046

7.  Altered brain activity during withdrawal from chronic alcohol is associated with changes in IL-6 signal transduction and GABAergic mechanisms in transgenic mice with increased astrocyte expression of IL-6.

Authors:  Donna L Gruol; Salvador Huitron-Resendiz; Amanda J Roberts
Journal:  Neuropharmacology       Date:  2018-05-19       Impact factor: 5.250

Review 8.  Autistic traits in epilepsy models: Why, when and how?

Authors:  Jana Velíšková; Jill L Silverman; Melissa Benson; Pierre-Pascal Lenck-Santini
Journal:  Epilepsy Res       Date:  2018-05-18       Impact factor: 3.045

9.  Effect of repeated alcohol exposure during the third trimester-equivalent on messenger RNA levels for interleukin-1β, chemokine (C-C motif) ligand 2, and interleukin 10 in the developing rat brain after injection of lipopolysaccharide.

Authors:  Lauren A Topper; C Fernando Valenzuela
Journal:  Alcohol       Date:  2014-10-05       Impact factor: 2.405

10.  IL-6 regulation of synaptic function in the CNS.

Authors:  Donna L Gruol
Journal:  Neuropharmacology       Date:  2014-11-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.